Hematologic Cancer Clinical Trials

The most recent listing of current clinical trials for hematologic and blood-related cancers — including blood and marrow transplant/BMT, leukemia, non-Hodgkins lymphoma, Hodgkin's disease/lymphoma and multiple myeloma — appears below.

Site: Hematologic/Blood-Related (Includes Blood and Marrow Transplant/BMT, Leukemia, Non-Hodgkins Lymphoma, Hodgkin's Disease/Lymphoma, Lymphoma and Multiple Myeloma)

Protocol ID    Title

ACETYLON-ACE-MM-102    Phase 1b / 2 Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with Relapsed-and-Refractory Multiple Myeloma

ACETYLON-ACY100    Phase I/II, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination with Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/ Refractory Multiple Myeloma

ARRAY-520-216-MM    Array-520-216: A Multicenter, Randomized, Open-label Phase 2 Study of Carfilzomib with or without ARRY-520 in Patients with Advanced Multiple Myeloma

ASTELLAS-CMV-0113-CL-1004    Astellas 0113-CL-1004: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

BMS-CA180399    An Open Label, Randomized (2:1) Phase 2b Study Of Dasatinib Vs. Imatinib In Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved An Optimal Response To 3 Months Of Therapy With 400 Mg Imatinib

CELATORCLTR0310-301    Phase III, Multicenter, Randomized, Trial Of CPX-351(cytarabine:daunorubicin) Liposome Injection Versus Cytarabine And Daunorubicin In Patients 60-75 Years Of Age With Untreated High Risk (Secondary) AML

CELGENECC-4047-MM-007    CelgeneCC-4047-MM-007: A Phase 3, Multicenter, Randomized, Openlabel Study To Compare The Efficacy And Safety Of Pomalidomide, Bortezomib And Low-dose Dexamethasone Versus Bortezomib And Low-dose Dexamethasone In Subjects With Relapsed Or Refractory Multiple Myeloma

CELGENECC-486-AML-001    Celgene CC-486-AML-001:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study To Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care As Maintenance Therapy In Subjects With Acute Myelogenous Leukemia In Complete Remission

CIBMTR09-PLEX    A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients with Hematological Malignancies

CTN0901    A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intesnsity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

CTN-0903    Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic syndromes in HIV-Infected Individuals

CTN-1101    A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies

CYCLACEL-CYC6812-12    A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

ECOG-1411    Intergroup Randomized Phase II Four Arm Study In Patients > 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB - R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV-R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RB- LR)

ECOG-1412    Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

ECOG-2408    A 3 Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Rituximab vs. BR Followed by Lenalidomide/ Rituximab in High Risk Follicular Lymphoma

ECOG-2905    Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid ®) Alone in Combination with Epoetin Alfa (Procrit ®) in Subjects with Low- or Intermediate -1 Risk MDS and Symptomatic Anemia

ECOG-2906    Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years)

ECOG-3903    Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders

ECOG-4412    A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

ECOG-M9177    Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma

FHCRC-2230    A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA Haploidentical Hematopoietic Cell Transplantation

GILEAD-GS-US-312-0115    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

GILEAD-GS-US-312-0117    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL 101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

GILEAD-GS-US-313-0124    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of I delalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma

GILEAD-GS-US-313-0125    A Phase 3, Randomized,Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphoma

GSK-TRC114968    A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-Label, Part 2: Randomized, Double-Blind, Part 3: extension)

IIT-DRYOBYSKI-TOCILUZUMAB    Phase I-II Study Using Tocilizumab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

IIT-HAMADANI-ATORVASTATIN    Phase II Study Of Atorvastatin, Micro-Dose Methotrexate And Tacrolimus Administered Only To Transplant Recipients For The Prophylaxis Of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

IIT-MILLENNIUM-X16016    Phase I study of vincristine, doxorubicin, Peg-asparaginase and dexamethasone (modified VXLD) plus MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia study

IIT-PRECLINVACCINEMM    Pre-Clinical Studies on Vaccines Derived From Patient-Derived Myeloma Cells

IIT-SCHIEKE-SIROLIMUS    Therapeutic Efficacy Of Topical Sirolimus In Early Stage Cutaneous T-Cell Lymphoma (CTCL)

KYOWA0761-010    Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

LILLY-JHTC    A Phase I Study of LY2784544 Testing Alternative Dosing Regimens in Patients with Myelofibrosis

MEI-004    A Phase II Open-Label, Single-Arm, Two-Stage, Multicenter Trial Of Pracinostat In Combination With Azacitidine In Elderly (age 65 plus Years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

MILLENNIUM-C16011    A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

MILLENNIUM-C25003    A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

NOVARTIS-CAMN107AUS37    A Phase II Randomized, Multicenter Study Of Treatment-Free Remission In Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Patients Who Achieve And Sustain MR4.5 After Switching To Nilotinib

ONYX2012-001    Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

ONYX-OPZ003    Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Combination With Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma

RDCRN-6503    Targeted Therapy of Bronchiolitis Obliterans Syndrome

SWOG-S1117    A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

SWOG-S1203    A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)